文献速递胸部肿瘤

AXL与易错DNA复制赋予EGFR突变肺癌耐药性并提供治疗策略

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

研究探讨EGFR突变肺癌经EGFR抑制剂治疗后是否激活易错DNA复制机制,发现药物耐受持留细胞及残留病灶患者中GAS6上调,AXL缺失可消除耐药,AXL过表达促进T790M出现;AXL通过诱导低保真DNA聚合酶及RAD18类泛素化激活易错复制,联合抗AXL治疗可治愈患者来源异种移植瘤。

要点

  • EGFRi治疗后的药物耐受持留细胞及残留病灶患者中GAS6上调,AXL缺失可消除耐药。
  • AXL过表达增强药物耐受持留细胞存活并加速T790M出现。
  • AXL诱导低保真DNA聚合酶并经类泛素化激活RAD18,驱动易错复制。

核心结论

  • 与细菌类似,肿瘤通过激活药理学可靶向的内源性突变因子来耐受治疗。
  • 阻断AXL驱动的易错复制过程可在异种移植模型中防止耐药,提供新的治疗策略。

研究设计与样本

  • 研究在循环药物耐受持留细胞和EGFRi治疗后残留病灶患者中观察GAS6上调,并进行AXL功能实验及患者来源异种移植瘤治疗实验。

主要发现

  • 在药物耐受持留细胞和EGFRi治疗后残留病灶患者中观察到GAS6上调,而敲除GAS6受体AXL可消除耐药。
  • AXL过表达增强药物耐受持留细胞存活并加速T790M出现。
  • 机制上,AXL诱导低保真DNA聚合酶并通过促进类泛素化激活其组织者RAD18。
  • 代谢组学发现AXL驱动MYC激活及嘌呤合成增加,且与嘧啶不平衡。
  • 将抗AXL联合治疗与药物耐受持留细胞向耐药细胞转变对齐可治愈患者来源异种移植瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether the treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in EGFRi-treated patients presenting residual disease, we observed upregulation of GAS6, whereas ablation of GAS6's receptor, AXL, eradicated resistance. Reciprocally, AXL overexpression enhanced DTP survival and accelerated the emergence of T790M, an EGFR mutation typical to resistant cells. Mechanistically, AXL induces low-fidelity DNA polymerases and activates their organizer, RAD18, by promoting neddylation. Metabolomics uncovered another hypermutator, AXL-driven activation of MYC, and increased purine synthesis that is unbalanced by pyrimidines. Aligning anti-AXL combination treatments with the transition from DTPs to resistant cells cured patient-derived xenografts. Hence, similar to bacteria, tumors tolerate therapy by engaging pharmacologically targetable endogenous mutators. SIGNIFICANCE: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators are activated in drug-treated cells, and this heralds tolerance. Blocking the process prevented resistance in xenograft models, which offers new treatment strategies. This article is highlighted in the In This Issue feature, p. 2483.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Noronha A, Belugali Nataraj N, Lee JS, et al. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discov. 2022. PMID: 35895872. doi:10.1158/2159-8290.CD-22-0111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。